Indeed, we identified two drugs, Tx-1123 and PFK15, with preferential activity in Cic-deficient tumor cells, suggesting that these drugs may be an alternative for patients who develop resistance via mutation of CIC. While the pleiotropic effects of Tx-1123 make it difficult to predict how this drug could preferentially affect Cic-deficient cells (Hori et al, 2002), PFK15 specifically targets the rate-limiting glycolytic enzyme PFKFB3 (Shi et al, 2017; Clem et al, 2013). This evidence concerns the gene HK1 and neoplasm.